StockData
Amgen Inc logo

Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3023% above fair value
$443.89−14.04 (-3.07%)

Close on Nov 18, 2026Market cap $239.98BP/E 25.7Yield 2.18%

Amgen pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Amgen's pe ratio was 29.1× on Nov 11, 2026, against 26.7× a year earlier. Over the last 5 years it ranged from 15.0× to 57.4×, with a median of 24.3×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202629.1×+3.8
2025Dec 31, 202525.3×−8.0
2024Dec 31, 202433.3×+12.9
2023Dec 29, 202320.5×−0.6
2022Dec 30, 202221.0×+2.4
2021Dec 31, 202118.6×+0.8
2020Dec 31, 202017.9×−1.3
2019Dec 31, 201919.1×−33.5
2018Dec 31, 201852.6×+36.9
2017Dec 29, 201715.7×+1.1
2016Dec 30, 201614.6×−4.8
2015Dec 31, 201519.4×−5.7
2014Dec 31, 201425.1×+4.4
2013Dec 31, 201320.7×−0.7
2012Dec 31, 201221.3×+8.0
2011Dec 30, 201113.3×+1.5
2010Dec 31, 201011.9×−0.8
2009Dec 31, 200912.7×–

More Amgen figures

See a number that looks wrong?